

## REFERENCES

- [1] United states pharmacopeia USP 40-NF35
- [2] The British pharmacopeia 2017
- [3] Ph. Eur Supplement 9.2
- [4] International Conference on Harmonization: (2000), Federal Register Q3A(R) 65 (140): 45085.
- [5] International Conference on Harmonization (2000) Draft Revised Guidance On Impurities In New Drug Products. Federal Register Q3B(R) 65 (139): 44791.
- [6] Guideline for elemental impurities Q3D
- [7] Z. Xu, J. Hwang, R. Greenlund, X. Huang, J. Luo, S. Anschutz, quantitative determination of metallic Iron content in steel-making slag, *Journal of Minerals & Materials Characterization & Engineering*, 2 (2003) 65-70.
- [8] J. Triglav, J. T. Van Elteren, V.S. Šelih, Basic modeling approach to optimize elemental imaging by laser ablation ICPMS, *Analytical Chemistry*, 82 (2010) 8153-60.
- [9] K.Vaughn, L. Dussubieux, P.R. Williams, A pilot compositional analysis of Nasca ceramics from the Kroeber collection, *Journal of Archaeological Science*, 38 (2011) 3560-3567.
- [10] B.Wagner, W. Jędral, Open ablation cell for LA-ICP-MS investigations of historic objects, *Journal of Analytical Atomic Spectrometry*, 26 (2011) 2058-2063.
- [11] G. Sarah, B. Gratuze, J.N. Barrandon, Application of laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) for the investigation of ancient silver coins, *Journal of Analytical Atomic Spectrometry*, 22 (2007) 1163-1167.
- [12] International Conference on Harmonization: (1997) Impurities, Q3C- Guidelines for Residual Solvents, Q3C. Federal Register 62(247): 67377.

- [13] A.A. Deshpande, B. Sirisha B, G.R. Deshpande, J.M. Babu, R.M. Krishna, I.M. Rao, Identification and quantification of an unknown peak in residual solvent analysis by GC using relative response factor, *Int J Pharm Sci Res*, 7 (2016) 1338-1347.
- [14] S. Klick, A. Skold, Validation of a generic analytical procedure for determinations of residual solvents in drug substances, *J. Pharm. Biomed. Anal*, 36, (2004) 401-409.
- [15] Gang Shaoa, Roger Kautzc, Shiqi Pengd, Guohui Cuid, W. Roger. B. Giesea, Calibration by NMR for quantitative analysis: p-Toluenesulfonic acid as a reference substance. *J.Chromatography A*, 1138 (2007) 305–308,
- [16] International Conference on Harmonization: (1999) Specifications, Q6A: Test Procedures and Acceptance Criterial for New Drug Substances and New Drug Products. *Chemical substances* 65 (146):67488.
- [17] Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7
- [18] W.J. Murphy, Editorial. What is Analysis? What is the Role of the Analyst?, *Anal. Chem.*, 19 (1947) 821-823.
- [19] B.L. Clarke, Introductory Remarks, *Anal. Chem.*, 19 (1947), 943.
- [20] F.C. Strong, Trends in Quantitative Analysis, *Anal. Chem.*, 19 (1947) 968-971.
- [21] S. Lindsay, High Performance Liquid Chromatography, ACOL Series (1992).
- [22] K. Robards, P.R. Haddad, P.E. Jackson, Principles and Practice of Modern Chromatographic Methods, Academic Press (1994).
- [23] V.R. Meyer, Wiley, Chichester: Practical High Performance Liquid Chromatography (1994).
- [24] J.W. Dolan, L.R. Snyder, N.M. Djordjevic, D.W. Hill, T.J. Waeghe, Reversed-phase liquid chromatographic separation of complex samples by optimizing temperature and gradient time: I. Peak capacity limitations, *J. Chromatogr. A*, 857 (1999) 1–20.

- [25] J.W. Dolan, L.R. Snyder, N.M. Djordjevic, D.W. Hill, T.J. Waeghe, Reversed-phase liquid chromatographic separation of complex samples by optimizing temperature and gradient time: II. Two-run assay procedures, *J. Chromatogr. A*, 857 (1999) 21–39.
- [26] J.W. Dolan, L.R. Snyder, R.G. Wolcott, P. Haber, T. Baczer, R. aliszan, L.C. Sander, Reversed-phase liquid chromatographic separation of complex samples by optimizing temperature and gradient time III. Improving the accuracy of computer simulation, *J. Chromatogr. A*, 857(1999) 41–68.
- [27] U.D. Neue, *HPLC Columns: Theory, Technology, and Practice*, Wiley-VCH, New York, 1997, p.316.
- [28] McCalley, D. V. *Anal. Chem.* 2006, 78, 2532.
- [29] N.S. Wilson , M.D. Nelson , J.W. Dolan , L.R. Snyder , R.G. Wolcott , P.W. Carra, C olumn selectivity in reversed-phase liquid chromatography I. A general quantitative relationship, *Journal of Chromatography A*, 961 (2002) 171–193.
- [30] I. N. Ackworth, *Coulometric Electrode Array Detectors for HPLC (Progress in HPLC-HPCE, Vol. 6)*, Brill Academic, Boston, 1997.
- [31] L. R. Snyder and J. J. Kirkland, *Introduction to Modern Liquid Chromatography*, 1<sup>st</sup> edition Wiley, New York, (1979) 136.
- [32] L. R. Snyder and J. W. Dolan, *High-Performance Gradient Elution*, Wiley, New York (2007).
- [33] J. C. Sternberg, R. A. Keller, *Advances in Chromatography*, Dekker, New York, 2 (1966) 205.
- [34] D. Parriott, San Diego, *A Practical Guide to HPLC Detection*, 1993.
- [35] L. R. Snyder, J. W. Dolan, *High-Performance Gradient Elution*, Wiley, Hoboken, (2007).
- [36] L. R. Snyder, J. J. Kirkland, J. L. Glajch, *Practical HPLC Method Development*, Wiley-Interscience, New York, (2)1997.

- [37] P. Brown, E. Grushka, *Design of Rapid Gradient Methods for the Analysis of Combinatorial Chemistry Libraries and the Preparation of Pure Compounds*, Dekker, New York, 2001
- [38] International Organization for Standardization. *Guide 8402: Quality Vocabulary*, ISO, Geneva, (1994).
- [39] U.S. FDA, Title 21 of the U.S. Code of Federal Regulations: 21 CFR 211, Current good manufacturing practice for finished pharmaceuticals.
- [40] U.S.FDA - *Guidance for Industry (draft) Analytical Procedures and Methods Validation: Chemistry, Manufacturing and Controls and Documentation: (2000)*.
- [41] ISO/IEC 17025: *General requirements for the competence of testing in calibration laboratories*, (2005).
- [42] International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, *Validation of analytical procedures: Methodology*, adopted in (1996), Geneva.
- [43] U.S. EPA, *Guidance for methods development and methods validation for the Resource Conservation and Recovery Act (RCRA) Program*, Washington, D.C. (1995)., <http://www.epa.gov/sw-846/pdfs/methdev.pdf>
- [44] General Chapter 1225, *Validation of compendial methods*, United States Pharmacopeia 30, National Formulary 25, Rockville, Md., USA, The United States Pharmacopeial Convention, Inc: (2007).
- [45] *Reviewer Guidance: Validation of chromatographic methods*. Center for drug evaluation and research (CDER) 1994-615=023, 1302/02757, US Govt. printing office, Washington, DC, Nov 1994.
- [46] ICH “Draft guideline on validation of analytical procedures for pharmaceuticals; availability” *Fed. Reg.*, 59 (40) (March, 1994) 9750.
- [47] Full prescribing information of Tarceva- erlotinib hydrochloride tablet Genentech, Inc. Approval: 10/2016.

- [48] V. Rajesh, V. Jagathi, K. Sindhuri, G. DevalaRao, Spectrofluorimetric method for the estimation of erlotinib hydrochloride in pure and pharmaceutical formulations, *Electronic Journal of Chemistry*, 8 (2011) 304-308.
- [49] M. Padmalatha, S. Kulsum, C. Rahul, D. Thimma Reddy, G. Vidyasagar, Spectrophotometric methods for the determination of erlotinib in pure and pharmaceutical dosage forms, *International Journal Pharmaceutical Research and Development*, 3 (2011) 53-59.
- [50] B. Mandal, P. Balabathula, N. Mittal, G.C. Wood, H. Bhattacharjee, Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma, *J Fluoresc*, 22 (2012) 1425-1429.
- [51] V. K. Chakravarthy, D. G. Sankar, Development and validation of RP-HPLC method for estimation of erlotinib in bulk and its pharmaceuticals formulations, *Rasayan Journal of Chemistry*, 4 (2011) 393-399.
- [52] S. T. Latha, S. AnandaThangadurai, M. Jambulingam, K. Sereya, D. Kamalakannan, M. Anilkumar, Development and validation of RP-HPLC method for the estimation of erlotinib in pharmaceutical formulation, *Arabian Journal of Chemistry*, 4 (2013) 55-66.
- [53] K. Ravi Kumar, K. SankaraBabu, C.H. Nagabhushanam, A validated LC method for the estimation of erlotinib hydrochloride in bulk and tablet dosage form, *International Journal of Pharmacy and Biomedical Research*, 4 (2013) 01-04.
- [54] S.S. Pujeri, A.M.A. Khader, J.Seetharamappa, Validated stability-indicating chromatographic method for the assay of erlotinib active pharmaceutical ingredient, *Anal. Lett*, 42 (2011) 1855-1867.
- [55] G.S.S. Geetha, J. Raveendra Reddy, P. Ramalingam, P. Malleshwari, Validated RP-HPLC method for determination of erlotinibHCl in tablet dosage forms and its application to stress degradation studies, *Am. J. Pharm. Tech. Res*, 2 (2012) 842-852.

- [56] C. Karunakara, U. Aparna, V. Chandregowda, C.G. Reddy, Separation and determination of process-related impurities of erlotinib using reverse-phase HPLC with a photo-diode array detector, *Anal. Sci*, 28 (2012) 305–308.
- [57] L. Faivre, C. Gomo, O. Mir, F. Taieb, A. Schoemann-Thomas, S. Ropert, A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma, *J. Chromatogr. B*, 879 (2011) 2345–2350.
- [58] B. Soheila, D. Adeleh, V. Hadi, K. Arash, Z. M. Parvin, Development and application of an HPLC method for erlotinib protein binding studies, *Adv. Pharm. Bull*, 3 (2013) 289–293.
- [59] Y.A. Hou, L.M. Wei, D.T. Zhang, J. Zhang, D.W. Yang, Determination of erlotinib in rat plasma by HPLC and application to a pharmacokinetic study, *Lat. Am. J. Pharm*, 34 (2015) 980-984.
- [60] B. Mohammed Ishaq, V.S. ThiruvengadaRajan, S. AngalaParameswari, N. Amruth, M. Madhu, C. MadhusudanaChetty, Analytical method development and validation of erlotinib by high performance liquid chromatography, *Research J. Pharm. and Tech*, 4 (2011) 1787-1790.
- [61] Y. Zheng, A. Thomas-Schumann, L. Sakji, P. Boudou-Rouquette, N. Dupin, L. Mortier, M. Vidal, F. Goldwasser, B. Blanchet, An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients, *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci*, 928 (2013) 93-37.
- [62] G. Naveen Kumar Reddy, V.V.S. Rajendra Prasad, P.K. Maharana, Development and validation of a stability indicating uplc method for determination of erlotinib in pharmaceutical formulations, *Der PharmaChemica*, 4 (2012) 2288-2297.
- [63] A.V. Raju, N. Appalaraju, Development and validation of a LC-MS/MS method for the determination of erlotinib in Sprague dawley rat serum and its application to pharmacokinetic study, *Am. J. Phytomed. Clin. Ther*, 1 (2013) 83–97.

- [64] R.S.T. Satheeshmanikandan, K. Varanasi, S. Veeraraghavan, A. Rambabu, S. Chennupati, M. Rajamanickam, V. Swaroop, K. Mukkanti, Simultaneous determination of celecoxib, erlotinib and its metabolite desmethyl-erlotinib (OSI-420) in rat plasma by liquid chromatography/tandem mass spectrometry with positive/negative ion-switching electrospray ionisation, *Sci Pharm*, 80 (2012) 633–646.
- [65] R.M. Andrea, J.S. Christopher, R.J. David, The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography - Tandem mass spectrometry, *J. Chromatogr. B*, 848 (2007) 379–383.
- [66] A. Chahbouni, J.C. Den Burger, R.M. Vos, A. Sinjewel, A.J. Wilhelm, Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry, *Ther. Drug Monit*, 31 (2009) 683–687.
- [67] H. Zhang, L.M. Shi, W.Q. Chen, F.M. Shang, C.H. Mo, X.M. Wang, Validated LC-MS/MS method for the determination of Erlotinib in rat plasma, *Lat. Am. J. Pharm*, 34 (2015) 1293-1297.
- [68] A.A. Mahajan, P.B. Miniyar, A.S. Patil, R.U. Waghmare, , J.J. Patil, K. Mohanraj, R.N. Tiwari, Separation, identification and characterization of degradation products of erlotinib hydrochloride under ICH-recommended stress conditions by LC, LC-MS/TOF, *Journal of Liquid Chromatography and Related Technologies*, 38 (2015) 629-639.
- [69] B. M.Douglas, Raloxifene a selective estrogen receptor modulator (serm) with multiple target system effects, *The oncologist*, 5 ( 2000) 388-392
- [70] D.C. Pavithra, Lakshmi Sivasubramanian, New spectrophotometric determination of new spectrophotometric determination of new spectrophotometric determination of raloxifene hydrochloride in raloxifene hydrochloride in tablets, *Indian j. pharm. Sci*, 68 (2006) 375-376

- [71] B.Kalyanaramu, K.Raghubabu, Determination of raloxifene hydrochloride by oxidative coupling reaction in pharmaceutical formulations, *Int j App Pharm*, 3 (2011) 6-9.
- [72] K. Basavaiah U.R.Anil kumar, K. Tharpa, K. B. Vinay, Validated spectrophotometric methods for the determination of raloxifene hydrochloride in pharmaceuticals, *J. Chil. Chem. Soc*, 53 (2008) 1635-1639.
- [73] A.Sathyaraj, V. Satyanarayana, M.V. Basaveswara Rao, Gradient RP-HPLC method for the determination of purity and assay of Raloxifene hydrochloride in bulk drug, *Res.J.Chem.Sci*, 1 (2011) 9-16.
- [74] R.S Fernanda, F.C. Cristiane, M. Leonardo , B. Ana Maria, Development of alternative methods for the determination of raloxifene hydrochloride in tablet dosage form , *Brazilian Journal of Pharmaceutical Sciences*, 51( 2015) 349-360.
- [75] R.S. Phani, M.Useni reddy , K. R. S. Prasad, T. Mastnaiah, Development and validation of an HPLC-UV method for the determination of raloxifene and related products (impurities), *Rasayan j.chem*, 9 (2016) 878 – 888.
- [76] G. Sowjanya, M. M. Annapurna, J.V.L.N. Seshagiri Rao, Validated stability indicating liquid chromatographic method for the determination of raloxifene (anti-osteoporotic agent) in tablets, *Journal of drug delivery & therapeutics*, 2 (2012) 175-181.
- [77] D. Suneetha , A. Lakshmana rao, A new validated RP-HPLC method for the estimation of raloxifene in pure and tablet dosage form, *Rasayan j.chem*, 3 (2010) 117-121.
- [78] B. Vijay Kumar, K. Pratap Kumar, K. Suresh, A. Saheena, P. Srikanth, Y. Suneetha Development and validation of RP-HPLC method for determination of Raloxifene Hydrochloride from pharmaceutical preparation, *J. Chem. Pharm. Res*, 3 (2011) 784-791.



- [79] B. J. Stojanovic, T. Rakic, B. Slavkovic, N. Kostic, A. Vemic, A. Malenovic, Systematical approach in evaluation of LC method for determination of raloxifene hydrochloride and its impurities employing experimental design, *Journal of Pharmaceutical Analysis*, 3 (2013) 45–52.
- [80] G. Srinivas , G. V. Kanumula , P. Madhavan , K. Kishore Kumar , Y. R. Koti Reddy , M. Vishnu Priya<sup>1</sup>, K. Mukkanti, Development and validation of stability indicating method for the quantitative determination of raloxifene hydrochloride and its related impurities using UPLC, *J. Chem. Pharm. Res*, 3 (2011) 553-562.
- [81] S. Deepa , B. Sanjula, M. Ali, H. Patel, P. Jain, N.Sudhakar, J. Ali, Development and validation of a stability indicating reversed phase ultra performance liquid chromatographic method for the quantitative analysis of raloxifene hydrochloride in pharmaceutical dosage form, *Journal of Liquid Chromatography & Related Technologies*, 35 (2012) 162-173.
- [82] R. Buchi reddy, T. Venkateshwar goud , N. Nagamani, N. Pavan kumar, A. Alagudurai, R.Murugan, K.Parthasarathy, V.Karthikeyan, P. Balaji, Identification and characterization of potential impurities in raloxifene hydrochloride, *Sci Pharm*. 80 (2012) 605–617.
- [83] N. Jagadeesh, Y. Ravindra Kumara, A. Jayashreeb ,M. Sandeep, Structural elucidation of potential impurities of raloxifene hydrochloride by LC/ESI-MS and NMR. *Journal of Pharmacy Research* 8 (2014) 718-727.
- [84] T. Trdan, R.Roskar, J.Trontelj,M. Ravnkar, A.Mrhar, Determination of raloxifene and its glucuronides in human urine by liquid chromatography–tandem mass spectrometry assay. *Journal of Chromatography B*, 879 (2011) 2323-2331.
- [85] A. Solari, B. Uitdehaag, G. Giuliani, E. Pucci, C. Taus Aminopyridines for symptomatic treatment in multiple sclerosis. *Cochrane Database Syst Rev* 2001 :(4):CD001330.
- [86] P. Mishra, S. Ramteke, S.Panda, Dalfampridine sustained release tablet for the walking improvement in multiple sclerosis, *Proceedings in Int J Pharm Pharm Sci*, 8 (2016) 5-9

- [87] A.R. Korenke, M.P. Rivey, D.R.Allington, Sustained-release fampridine for symptomatic treatment of multiple sclerosis, *Ann Pharmacother* , 42 (2008)1458-1465.
- [88] C.H. Madhumathi, M. Padmalatha, Sneha, C.B. Divya. Development and validation of UV spectrophotometry method for the estimation of dalfampridine in tablets, *Int J Pharm Sci Res*, 2 (2014) 1019-1026.
- [89] H.M. Fatatry, S.F. Hammad, S.H. Elagamy. Validated spectrofluorimetric determination of dalfampridine in its synthetic mixture and spiked human plasma through derivatization with fluorescamine, *J Anal Tech*, 3 (2013) 23-26.
- [90] N.R. Dharani, K. Padmini, S. Sumakala. Stability indicating RP-HPLC method development and validation for estimation of dalfampridine in its bulk and formulation, *Int J Adv Res*, 4 (2016) 184-191.
- [91] S.Thomas , A. Bharti, S. Sanjeev, A. Ashutosh. A stability indicating simultaneous dual wavelength UV–HPLC method for the determination of potential impurities in fampridine active pharmaceutical ingredient, *J Pharm Biomed Anal*, 58 (2012) 136-140.
- [92] J.Mohit, S.Vishal, K.Rajesh, D.Vishal, S.G.Hiriyanna, Ajay Kumar, Determination of five potential genotoxic impurities in dalfampridine using liquid chromatography, *J Pharm Biomed Anal*, 133(2017) 27-31.
- [93] D. Jwal, C. Komal, J. Dharmin, P. Sanjay, J.M. Priti, RP-HPLC method for estimation of tiapriderel related substance in tablet formulation, *Int J Pharm Pharm Sci*, 7 (2015) 294-299.
- [94] P. Balamurugan, K. Anver Basha, J. Jeenet, G. Manish, P. Parthiban, A simple RP-HPLC method for simultaneous estimation of organic impurities, enantiomer and assay of dexlansoprazole, *Int J Pharm Pharm Sci*, 7 (2015) 347-52.
- [95] A. Suneetha, K. Raja Rajeswari, A high throughput flow gradient LC–MS/MS method for simultaneous determination of fingolimod, fampridine and prednisone in rat plasma, application to in vivo perfusion study, *J Pharm Biomed Anal*, 120 (2016) 10-18.

- [96] A. Suneetha , K. Raja Rajeswari , High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma, application to in vivo perfusion study, *Journal of food and drug analysis*, 24 (2016) 866-875.
- [97] A. van der Horst, P.N. De Goede, H.A. Van Diemen, C.H. Polman, H.J.Martens Determination of 4-aminopyridine in serum by solid-phase extraction and high-performance liquid chromatography, *J Chromatogr*, 574 (1992) 166-169.
- [98] Package leaflet, information for the user Lamivudine 150 mg film-coated tablets-07/2016.
- [99] R. Sharma, K. Mehta, Simultaneous spectrophotometric estimation of tenofovir disoproxil fumarate and lamivudine in three component tablet formulation containing efavirenz, *Indian J Pharm Sci*, 72 ( 2010) 527-530.
- [100] K. Anandakumar , K. Kannan, T. Vetrichelvan, Development and validation of emtricitabine and tenofovir disoproxil fumarate in pure and in fixed dose combination by UV spectrophotometry, *Dig J Nanomater Bios*, 6 (2011) 1085-1090.
- [101] S.V. Sutar, S.S.Patil, S.A.Pishvikar, H.N.More, Spectrophotometric method for degradation study of tenofovir disoproxil fumarate, *Int J Pharm Sci Res* , 3 (2012) 4363-4366.
- [102] B.Anindita, P. Aurobinda, M.A.Kumar, T.Chandra, Development and validation of spectrophotometric method for determination of emtricitabine and tenofovir disoproxil fumarate in bulk and tablet dosage form, *Int J Pharm Tech Res*, 3 (2011) 125-135.
- [103] B. Nyamweru, E. Kaale, V. Mugoyela, M.Chambuso, Development and validation of an HPTLC-densitometric method for simultaneous analysis of lamivudine, tenofovir disoproxil fumarate and efavirenz (LTE) in tablets, *J. Planar Chromatogr Mod TLC*, 26 (2013) 226-231.

- [104] D. Varma D, A. Lakshmana Rao, Stability-Indicating RP-HPLC Method for the Simultaneous estimation of efavirenz, tenofovir and emtricitabine in pharmaceutical formulations, *Indian journal of pharmacy and pharmacology*, 1 (2014) 1-17.
- [105] L.A.R. Prasad, J.V.L.N.S. Rao, P. Srinivasu, J. Hemalatha. New stability indicating HPLC method for simultaneous estimation of lamivudine, tenofovir and nevirapine in extended release tablets, *Int J Pharm*, 3 (2013) 136-144.
- [106] V.M Goud, A.S. Rao, S.R. Kumar, Method development and validation for simultaneous determination of lamivudine and tenofovir in tablet dosage form by RP-HPLC. *Int J Pharm Pharm Sci*, 5 (2013) 215-218.
- [107] P.H. Sonawane, P.S. Panzade, M.A. Kale, Simultaneous estimation of lamivudine and Tenofovir disoproxil fumarate in bulk and combined pharmaceutical dosage form by HPLC method, *Asian J Biomed Pharm Sci*, 3 (2013) 327-330.
- [108] K. Anandakumar , K. Kamarajanb, T. Vetrichelvan . A validated RP-HPLC method for simulataneous estimation of lamivudine and tenofovir disoproxil fumarate in pure and in tablet dosage form, *Eurasian J Anal Chem* 7 (2012) 56-66.
- [109] T. Sharma, N. Mishra, K. Swapan, C.S.I Sudam, D.G. Sankar, Validated RP-HPLC method for estimation of tenofovir disoproxil fumarate in bulk and pharmaceutical formulation, *Asian J Pharm Clin Res*, 5 (2012) 108-110.
- [110] S.B Dhara, N.P. Bhavini, N.P. Chhaganbhai, RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine and efavirenz in combined tablet dosage form, *Pharm Methods*, 3 (2012) 73-78.
- [111] H. Shweta, S.R. Dhaneshwar, Development and validation of a stability-indicating LC method for the determination of tenofovir disoproxil fumarate in pharmaceutical formulation, *Songklanakarin J Sci Technol*, 34 (2012) 615-22.
- [112] A. Srinath, B. Sneha B, A. Akhila, R. Ahmed, R.G Kulkarni, Method development and validation for simultaneous estimation of lamivudine, tenofovir and efavirenz in combined tablet dosage form by RP-HPLC and UV-spectroscopic method, *Int J Pharm Sci Res*, 5 (2014) 5491-5497.

- [113] K. Anandakumar, G. Abirami, S. Murugan, B. Ashok. RP-HPLC method for simultaneous estimation of lamivudine, tenofovir disoproxil fumarate and efavirenz in tablet formulation, *J Anal Chem*, 68 (2013) 815-821.
- [114] A. Dunge, C.Varalakshmi, V.V. Daisy, D. Sanjana, H. Jos, A. Ervin, Development of a validated liquid chromatographic method for the determination of related substances and assay of tenofovir disoproxil fumarate, *J Sep Sci*, 33 (2010) 1708-1716.
- [115] N.M.Rao, D.G. Sankar, Development and validation of stability-indicating HPLC method for simultaneous determination of lamivudine, tenofovir and dolutegravir in bulk and their tablet dosage form, *Future J Pharma Sci*, 1 (2015) 73-77.
- [116] S.K .Madeesh, Y.Ismail, V. Gunasekaran, Development and validation for simultaneous estimation of lamivudine, tenofovir and efavirenz by UPLC, *Int J Pharm*, 2 (2012) 656-660.
- [117] B.V. Purnima , T.V.B.Reddy , Y.S.Rao, G. Ramu, Stability indicating RP-UPLC method for assay of emtricitabine and tenofovir disoproxil fumarate in bulk and dosage forms, *Am J Analyt Chem*, 6 (2015) 807-821.
- [118] M.Kurmi, D.K.Singh, S.Tiwari, P. Sharma, S. Singh, Stability behavior of antiretroviral drugs and their combinations, characterization of interaction products of emtricitabine and tenofovir disoproxil fumarate by mass spectrometry, *J Pharm Biomed Anal*, 128 (2016) 438-446.
- [119] M.M.Krishna, B.Laxminarayana, P.N.Rao, I.J.Kumar, J.V.L.N.S. Rao, A novel LC-MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study, *Biomed Chromatogr*, 26 (2012) 1202-1209.
- [120] M.M. Krishna, P.N.Rao, I.J.Kumar, B. Laxminarayana, J.V.L.N.S. Rao. Simultaneous quantitation of lamivudine, zidovudine and nevirapine in human plasma by liquid chromatography–tandem mass spectrometry and application to a pharmacokinetic study, *Acta Pharm Sin B*, 2 (2012) 472–480.

- [121] Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents <http://aidsinfo.nih.gov/guidelines>
- [122] Atripla 600 mg/200 mg/300 mg film coated tablets patient information leaflet 04/2017
- [123] Authorized USP pending monograph tenofovir disoproxil fumarate tablets.
- [124] USP- 39, 3662 Efavirenz tablets USP official monograph.
- [125] Authorized USP pending monograph, version 1: lamivudine and stavudine tablets.
- [126] USP , 2012 Tenofovir disoproxil fumarate summary validation report.
- [127] A.M. Kumar, B. N. Sandhya, Mahesh Nasare, V.V.L.N Prasad, V. Prakash, V.Diwan, Development and validation of UV Spectrophotometric method for simultaneous estimation of lamivudine and efavirenz in the pharmaceutical dosage form, *J. Adv. Pharm. Edu. & Res*, 2 (2010) 210- 214.
- [128] A. Narendra, D. Deepika. A.Mathrusri, Determination of emtricitabine by derivative spectrophotometric method in pharmaceutical dosage forms, *chem sci trans*, 2 (2013) 978-982.
- [129] M. Sasikala, M. T. Deepthi, K. V. Kumar, B. N. M. Raja, Development and validation of UV spectrophotometric method for the simultaneous estimation of tenofovir disoproxil fumarate and emtricitabine in tablet dosage form by derivative spectroscopic method, *International Bulletin of Drug Research*, 5 (2013) 20-28.
- [130] S. Kulsum, G. V. Sagar, Determination of tenofovir and emtricitabine by simultaneous equation spectrophotometric method, *Journal of Pharmacy and Biological Sciences*, 11 (2016) 111-115.
- [131] A. Behera, A. Parida, M. Amit Kumar, D. Gowri Sankar, M.S Kumar, S. Chandra, Development and Validation of Spectrophotometric method for determination of emtricitabine and tenofovir disoproxil fumarate in bulk and tablet dosage, *Int.J. PharmTech Res*, 3 (2011) 1874-1882.

- [132] M. Madhuri, K. Vijaya Sri, G. Vinay Jain, Simultaneous estimation and validation of tenofovir disoproxil fumarate, emtricitabine and rilpivirine hydrochloride in pharmaceutical dosage form by uv- spectrophotometry, *Indo American Journal of Pharmaceutical Research*, 4 (2014) 5864- 5873.
- [133] K. Deepthi, G. Nagarjuna Reddy, K. Dhanalakshmi, Method development and validation for simultaneous estimation of emtricitabine and tenofovir disoproxil fumarate in pure and tablet dosage form by using RP-HPLC, *International Journal of Pharma Research & Review*, 2 (2013) 1-11.
- [134] V.P.V.S.Koteswara Rao, K. Kranthi Kumar, T. VenkataRaveendranath, P.LeelaMadhuri, K.Sasikanth, RP-HPLC method for the simultaneous estimation of emtricitabine, tenofovir and efavirenz in pharmaceutical dosage form, *journal of Global Trends in Pharmaceutical Sciences*, 2 (2011) 177-186.
- [135] S. Rajesh, G. Pooja, A validated RP - HPLC method for simultaneous estimation of emtricitabine and tenofovir disoproxil fumarate in a tablet dosage form, *Eurasian J. Anal. Chem*, 4 (2009) 276-284.
- [136] C. Palavan, L.A Ramaprasad, P.Srinivasu, J.V.L.N. Seshagiri Rao, A new RP-HPLC method for the simultaneous estimation of emtricitabine, efavirenz and tenofovir in tablet dosage forms, *Am. J. PharmTech Res*, 3 (2013) 547 -555.
- [137] AD Mali, UB More, RP-HPLC method for simultaneous estimation of impurities from emtricitabine and tenofovir disoproxil fumarate tablet, *Int J Pharma Sci Res*, 7 (2016) 1662-1669.
- [138] P. Tiwari, Y. Ravi , K. Avinash, V.Vaidya, P.A.Sathe, G. Deepali, Development and validation of UPLC method for emtricitabine, tenofovir and efavirenz in pharmaceutical preparation, 9 (2010) 247- 251.
- [139] P.L.N Revathi, P.Prahlad, S.K.Mastanamma, N.Ravindra, M.V.B.Rao , uplc separation analysis of emtricitabine, tenofovir, cobicistat and elvitegravir from their degradation products, *Int J Pharm Pharm Sci*, 8 (2016) 362-369.

- [140] N. Sreekanth and J. T Jacob, UPLC method for the quantitative estimation of emtricitabine impurities in formulated drug product, *Der Pharmacia Lettre*, 7 (2015) 160-164.
- [141] K.Y. Kavitha, G.Getha, R.Hariprasad, R.Venkatarayanan, M.Kaviarasu, Development and validation of RP-UPLC analytical method for simultaneous estimation of emtricitabine , raltegravir, tenofovir disoproxil fumarate and its pharmaceutical dosage forms. *Int res journal of pharmacy*, 4 (2013) 150-155.